Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 18% in premarket trading.
Moderna shares plunge after company cuts vaccine sales outlook
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%
Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death was reported in the U.S. The stock has lost about two-third of its value over the past year and is well off its all-time high near $490 in August 2021, during the COVID-19 pandemic.
Moderna stock plunges 20% after company lowers 2025 sales forecast by $1 billion
Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory syncyti | Against the backdrop of poor sales for the company’s COVID-19 shot Spikevax and its recently approved RSV prophylactic mRESVIA,
Moderna shares tumble on slashed sales guidance
Moderna lost more than $3 billion in maker value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.
Moderna shares slide after sales guidance slashed
Moderna shares dropped as much as 22 per cent on Monday after the US biotech group’s sales forecasts disappointed investors.
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.07 in late morning trading Monday. The stock has tumbled 93% from its five-year high of $456.76 in August 2021.
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Moderna shares drop 19% after 2025 revenue guidance falls below estimates
EST Moderna (MRNA) shares drop 19% after 2025 revenue guidance falls below estimatesStay Ahead of the Market:Discover outperforming
Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) ...
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
Moderna Crashes 21%. 'No Inflection In Sight' After Guidance Cut, CMV Shortfall.
Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting ...
Moderna’s stock tumbles to post-COVID lows after revenue outlook disappoints
Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
Moderna stock takes a 20% hit: here’s why
Moderna lowers its full-year sales guidance by up to $1.0 billion. Moderna stock is now down close to 30% versus its YTD high ...
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...
A Norovirus Vaccine May Be Coming
“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...
Macy's, Abercrombie and Moderna fall premarket; Sage soars
Here are some of the biggest premarket US stock movers today: Macy’s (NYSE: M) stock fell 3.4% after the retailer said it ...